Optimization & Functional Characterization of MYC RNA-Targeting Small Molecules

• Elucidating compound mechanism by defining how mRNA-targeted MYC repression drives modulation of the MYC transcriptional network
• Demonstrating in vivo efficacy to show translation from cellular activity into disease-relevant models
• Enhancing efficacy by refining potency, exposure, and selectivity

Speakers:

David Sparkman-Yager

Co-Founder & Chief Technology Officer

Wayfinder Biosciences